Opinion Split On Auxilium’s Phase III Effort
This article was originally published in The Pink Sheet Daily
Executive Summary
Doctor slip-ups injecting Xiaflex likely caused trouble, analyst tells “The Pink Sheet” DAILY.
You may also be interested in...
Pfizer And Auxilium Set Partnership For European Rights To Xiaflex
For $75 million upfront plus milestones and royalties, Pfizer gets Xiaflex rights for two indications in 46 countries.
Pfizer And Auxilium Set Partnership For European Rights To Xiaflex
For $75 million upfront plus milestones and royalties, Pfizer gets Xiaflex rights for two indications in 46 countries.
Xiaflex Risk/Benefit Profile Acceptable Despite Tendon Ruptures, Auxilium Says
Phase III data supports Xiaflex injection as alternative to surgery for treating Dupuytren’s contracture.